Immunovant Inc (IMVT : NASDAQ)
Common Stock
$28.41
USD
-0.76 (-2.61%)
Last updated: 2026-11-02
Follow IMVT
IMVT
Immunovant Inc
WealthAwesomePerformance
1 Day
-2.61%
1 Week
+0.85%
1 Month
-15.50%
YTD
-18.15%
Key Statistics
Market Cap
$6.03B
52W High
$45.42
52W Low
$21.43
P/E Ratio
-
50 Day MA
$34.56
200 Day MA
$32.04
Beta
0.84
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/2/2026 | $29.32 | $29.64 | $28.38 | $28.41 | $28.41 | 1,268,029 |
| 10/30/2026 | $29.49 | $29.78 | $28.75 | $29.17 | $29.17 | 1,165,400 |
| 10/29/2026 | $29.56 | $30.15 | $29.33 | $29.64 | $29.64 | 1,399,285 |
| 10/28/2026 | $28.50 | $29.47 | $28.41 | $29.42 | $29.42 | 1,239,674 |
| 10/27/2026 | $28.25 | $28.96 | $28.00 | $28.88 | $28.88 | 1,057,299 |
| 10/26/2026 | $28.46 | $28.50 | $27.63 | $28.17 | $28.17 | 1,195,303 |
| 10/23/2026 | $28.93 | $28.93 | $28.14 | $28.41 | $28.41 | 641,300 |
| 10/22/2026 | $28.09 | $29.12 | $27.98 | $29.10 | $29.10 | 1,156,421 |
| 10/21/2026 | $28.97 | $29.18 | $28.05 | $28.38 | $28.38 | 1,494,791 |
| 10/20/2026 | $27.76 | $29.14 | $27.62 | $28.59 | $28.59 | 1,440,031 |
Analyst Price Targets
Based on 17 analysts covering IMVT · as of Oct 5, 2026
Wall Street analysts forecast IMVT stock price to rise 72.0% over the next 12 months.
Consensus
Buy4.41 / 5.00
Avg. Target
US$48.88
+72.0% Upside
Current Price
US$28.41
Last close
Analyst Breakdown (17 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IMVT's historical volatility
30-Day Vol
39.7%
Annualized
90-Day Vol
35.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$23.76
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$26.77 | US$23.34 – US$30.70 |
| 60 trading days | US$25.22 | US$20.78 – US$30.61 |
| 90 trading days | US$23.76 | US$18.74 – US$30.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-565.61M
- Profit Margin
- 0.00%
- ROE (TTM)
- -80.10%
- EPS (Diluted)
- -2.82
- Book Value
- 3.56
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About IMVT.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| VCIG | VCI Global Limited Ordinary Share | $8.16 | +4728.40% |
| RETO | ReTo Eco-Solutions Inc | $4.16 | +647.26% |
| BJDX | Bluejay Diagnostics Inc | $2.12 | +281.02% |
| INO | Inovio Pharmaceuticals Inc | $1.89 | +215.00% |
| CLRO | ClearOne Inc | $5.65 | +65.69% |
| INLF | INLIF LIMITED Ordinary Shares | $0.29 | +56.76% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.06 | +55.50% |
| GENVR | Gen Digital Inc. Contingent Value Rights | $2.85 | +52.41% |
IMVT.US news timeline
1 article covering IMVT.US, most recent first
Latest